Amanda Cantin is a pharmacist who is specialized in Critical Care in New York, New York. Patients can reach her at 281 1st Ave, New York or contact her on 212-844-5259. Active license number of Amanda Cantin is 059922 for Critical Care in New York. Amanda Cantin is a licensed pharmacist who has demonstrated specialized knowledge and skill in the delivery of patient care services by pharmacists, as integral members of interprofessional teams, working to ensure the safe and effective use of medications in critically ill patients.
Complete Profile:
Amanda Cantin speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Amanda Cantin
Specialization:
Critical Care
Credentials:
PHARMD
Gender:
Female
Location:
281 1st Ave, New York, New York, 10003-2925
Phone:
212-844-5259
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Amanda Cantin are as mentioned below.
NPI Number:
1215417050
NPI Enumeration Date:
21 Aug, 2018
NPI Last Update On:
21 Aug, 2018
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Amanda Cantin are as mentioned below.
Specialization
License Number
State
Status
Critical Care
059922
New York
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
38 Delancey St Apt 13c, New York, New York
Zip:
10002-4197
Phone Number:
719-201-9041
Fax Number:
--
Patients can reach Amanda Cantin at 281 1st Ave, New York, New York or can call on phone at 212-844-5259.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 09 December, 2024.